Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
Holding CERS?
Track your performance easily
CERS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.38 - $2.59
Previous Close$1.58
Volume2.38M
Average Volume (3M)1.55M
Market Cap
$293.43M
Enterprise Value$316.56M
Total Cash (Recent Filing)$75.56M
Total Debt (Recent Filing)$97.90M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Feb 20, 2025EPS Estimate
-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding185,715,415
10 Day Avg. Volume1,216,789
30 Day Avg. Volume1,549,069
Standard Deviation0.15
R-Squared0.18
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)5.45
Price to Sales (P/S)1.67
Price to Cash Flow (P/CF)18.00
P/FCF Ratio21.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda-29.70
Forecast
1Y Price Target
$4.00Price Target Upside153.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cerus News
PremiumCompany Announcements
Cerus Corporation Reports Strong Q3 2024 Financials
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCERS is making progress towards profitability, reporting positive adjusted EBITDA in 3Q, a significant improvement from the previous year's loss.
Product DevelopmentThe rollout of IFC continues to gain momentum, with sales driven by more standing orders and deeper utilization within existing accounts.
Strategic PartnershipsCERS has entered into a new six-year agreement with BARDA to support the INTERCEPT RBC development program.
Bears Say
Approval SetbacksThe company's application for INTERCEPT RBC had previously been under review by the EU Competent Authority and was completed without granting approval.
Data InsufficiencyThe EU Competent Authority, CBG, concluded that the data are insufficient to support the proposed classification of the impurity profile of the final product in CERS' application for INTERCEPT RBC.
Regulatory ChallengesThe review of CERS's CE Mark application for INTERCEPT RBC was completed without receiving approval, prompting the company to assess new strategies for regulatory submission.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.38 and its highest was $2.58 in the past 12 months.
What is Cerus Corp’s market cap?
Currently, no data Available
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Feb 20, 2025 which is in 61 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Oct 30, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.012.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -$0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 185,715,410 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -8.721%.
Which hedge fund is a major shareholder of Cerus Corp?
Among the largest hedge funds holding Cerus Corp’s share is Baker Bros Advisors LP. It holds Cerus Corp’s shares valued at 34M.
---
Cerus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (153.16% Upside)
$4.00 (153.16% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.11%
12-Months-Change
Fundamentals
Return on Equity
-38.81%
Trailing 12-Months
Asset Growth
-7.92%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
---
CERS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarterly performance with positive trends in revenue growth and business expansion, particularly in the North American market and the INTERCEPT Fibrinogen Complex business. However, challenges such as a decline in government contract revenue and regulatory hurdles in Europe were noted. Overall, the positive aspects significantly outweigh the negatives, indicating a positive outlook.Read More>---
CERS Stock 12 Month Forecast
Average Price Target
$4.00
▲(153.16% Upside)
Technical Analysis
Best Analysts Covering CERS
1 Year
1 Year Success Rate
4/20 ratings generated profit
1 Year Average Return
-18.59%
assigned a buy rating 2 months ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -18.59% per trade.
---